{"preliminary_commentary":{"by_channel":{"x_thread":10},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT00430365\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["lenalidomide"]],"indication":"multiple myeloma after autologous stem cell transplantation","name":"IFM2005-02","nct_id":"NCT00430365","offer":{"currency":"USD","how":"Buy the first edition with create_order on https://mcp.erudio.com/mcp (product \"first_edition\", report \"NCT00430365\", the buyer's work email and organization), or POST https://www.erudio.com/api/orders with the same fields. It returns a Stripe checkout_url for your person to pay by card; a first edition has no agent-wallet payment. The person can also order on https://www.erudio.com/trials/ifm2005-02-nct00430365. We build the first edition within 24 hours of payment and email it to you once it passes our checks and review. If your report can't be delivered, we'll contact you and refund it in full.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"product":"first_edition","size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"IFM2005-02","arms":[{"description":"Administration of oral placebo","label":"placebo group","type":"PLACEBO_COMPARATOR"},{"description":"Administration of lenalidomide","label":"lenalidomide group","type":"EXPERIMENTAL"}],"collaborators":["Intergroupe Francophone du Myelome","Celgene"],"completion_date":{"date":"2018-09","type":"ACTUAL"},"conditions":["Myeloma"],"enrollment":{"count":614,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"lenalidomide","otherNames":["REVLIMID"],"type":"DRUG"},{"name":"placebo","otherNames":[],"type":"DRUG"}],"last_update":"2026-04-06","lead_sponsor":"University Hospital, Toulouse","official_title":"Relevance of Maintenance Therapy Using Lenalidomide (Revimid®) After Autologous Stem Cell Transplantation Patients Under the Age Of 65. (Open, Randomised, Multi-centric Trial Versus Placebo).","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2017-09","type":"ACTUAL"},"primary_outcomes":[{"measure":"Determine the efficacy of Revlimid® at prolonging the duration of the post-transplant response.","timeFrame":"2 years"}],"references":[{"citation":"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol. 1998 Dec;16(12):3832-42. doi: 10.1200/JCO.1998.16.12.3832.","pmid":"9850028","type":"BACKGROUND"},{"citation":"Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L, Garderet L, Decaux O, Leyvraz S, Vekemans MC, Voillat L, Michallet M, Pegourie B, Dumontet C, Roussel M, Leleu X, Mathiot C, Payen C, Avet-Loiseau H, Harousseau JL; IFM Investigators. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10;366(19):1782-91. doi: 10.1056/NEJMoa1114138.","pmid":"22571202","type":"RESULT"}],"start_date":{"date":"2006-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Maintenance Therapy Using Lenalidomide in Myeloma","url":"https://clinicaltrials.gov/study/NCT00430365"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ifm2005-02-nct00430365"}